BACKGROUND & AIMS: Intestinal metaplasia (IM) and spasmolytic polypeptide-expressing metaplasia (SPEM) are precursors to gastric carcinogenesis. We sought to identify molecular biomarkers of gastric metaplasias and gastric cancer by gene expression profiling of metaplastic lesions from patients. METHODS: Complementary DNA microarray analysis was performed on IM and SPEM cells isolated from patient samples using laser capture microdissection. Up-regulated transcripts in metaplastic lesions were confirmed by immunostaining analysis in IM, SPEM, and gastric cancer tissues. Proteins that were highly expressed specifically in gastric cancer tissues were analyzed for their association with survival in a test set (n = 450) and a validation set (n = 502) of samples from gastric cancer patients. RESULTS: Compared with normal chief cells, 858 genes were differentially expressed in IM or SPEM samples. Immunostaining was detected for 12 proteins, including 3 new markers of IM (ACE2, LGALS4, AKR1B10) and 3 of SPEM (OLFM4, LYZ, DPCR1). Of 13 proteins expressed in IM or SPEM, 8 were expressed by 17%-50% of human gastric cancer tissues (MUC13, OLFM4, CDH17, KRT20, MUC5AC, LGALS4, AKR1B10, REG4). Expression of CDH17 or MUC13 correlated with patient survival in the test and validation sets. Multivariate analysis showed that CDH17 was an independent prognostic factor in patients with stage I or node-negative disease. CONCLUSIONS: We identified several novel biomarkers for IM, SPEM, and gastric cancer using gene expression profiling of human metaplastic lesions. Expression of CDH17 and MUC13 was up-regulated in gastric cancer tissues. CDH17 is a promising prognostic marker for early stage gastric cancer. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
BACKGROUND & AIMS:Intestinal metaplasia (IM) and spasmolytic polypeptide-expressing metaplasia (SPEM) are precursors to gastric carcinogenesis. We sought to identify molecular biomarkers of gastric metaplasias and gastric cancer by gene expression profiling of metaplastic lesions from patients. METHODS: Complementary DNA microarray analysis was performed on IM and SPEM cells isolated from patient samples using laser capture microdissection. Up-regulated transcripts in metaplastic lesions were confirmed by immunostaining analysis in IM, SPEM, and gastric cancer tissues. Proteins that were highly expressed specifically in gastric cancer tissues were analyzed for their association with survival in a test set (n = 450) and a validation set (n = 502) of samples from gastric cancerpatients. RESULTS: Compared with normal chief cells, 858 genes were differentially expressed in IM or SPEM samples. Immunostaining was detected for 12 proteins, including 3 new markers of IM (ACE2, LGALS4, AKR1B10) and 3 of SPEM (OLFM4, LYZ, DPCR1). Of 13 proteins expressed in IM or SPEM, 8 were expressed by 17%-50% of humangastric cancer tissues (MUC13, OLFM4, CDH17, KRT20, MUC5AC, LGALS4, AKR1B10, REG4). Expression of CDH17 or MUC13 correlated with patient survival in the test and validation sets. Multivariate analysis showed that CDH17 was an independent prognostic factor in patients with stage I or node-negative disease. CONCLUSIONS: We identified several novel biomarkers for IM, SPEM, and gastric cancer using gene expression profiling of human metaplastic lesions. Expression of CDH17 and MUC13 was up-regulated in gastric cancer tissues. CDH17 is a promising prognostic marker for early stage gastric cancer. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: Nick Barker; Meritxell Huch; Pekka Kujala; Marc van de Wetering; Hugo J Snippert; Johan H van Es; Toshiro Sato; Daniel E Stange; Harry Begthel; Maaike van den Born; Esther Danenberg; Stieneke van den Brink; Jeroen Korving; Arie Abo; Peter J Peters; Nick Wright; Richard Poulsom; Hans Clevers Journal: Cell Stem Cell Date: 2010-01-08 Impact factor: 24.633
Authors: Charles M Leys; Sachiyo Nomura; Erin Rudzinski; Michio Kaminishi; Elizabeth Montgomery; Mary Kay Washington; James R Goldenring Journal: Hum Pathol Date: 2006-07-07 Impact factor: 3.466
Authors: C Grötzinger; J Kneifel; D Patschan; N Schnoy; I Anagnostopoulos; S Faiss; R Tauber; B Wiedenmann; R Gessner Journal: Gut Date: 2001-07 Impact factor: 23.059
Authors: A H Ormsby; M F Vaezi; J E Richter; J R Goldblum; T W Rice; G W Falk; T L Gramlich Journal: Gastroenterology Date: 2000-09 Impact factor: 22.682
Authors: David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245
Authors: Victoria G Weis; Josane F Sousa; Bonnie J LaFleur; Ki Taek Nam; Jared A Weis; Paul E Finke; Nadia A Ameen; James G Fox; James R Goldenring Journal: Gut Date: 2012-07-07 Impact factor: 23.059
Authors: Won Jae Huh; Shradha S Khurana; Jessica H Geahlen; Kavita Kohli; Rachel A Waller; Jason C Mills Journal: Gastroenterology Date: 2011-10-14 Impact factor: 22.682
Authors: Kaisa Thorell; Johan Bengtsson-Palme; Oscar Hsin-Fu Liu; Reyna Victoria Palacios Gonzales; Intawat Nookaew; Linda Rabeneck; Lawrence Paszat; David Y Graham; Jens Nielsen; Samuel B Lundin; Åsa Sjöling Journal: Infect Immun Date: 2017-09-20 Impact factor: 3.441
Authors: Shradha S Khurana; Terrence E Riehl; Benjamin D Moore; Matteo Fassan; Massimo Rugge; Judith Romero-Gallo; Jennifer Noto; Richard M Peek; William F Stenson; Jason C Mills Journal: J Biol Chem Date: 2013-04-15 Impact factor: 5.157